Pamela Connealy
2021
In 2021, Pamela Connealy earned a total compensation of $2.7M as Chief Financial Officer at Pyxis Oncology.
Compensation breakdown
| Non-Equity Incentive Plan | $252,500 |
|---|---|
| Option Awards | $2,268,661 |
| Salary | $195,453 |
| Other | $18,750 |
| Total | $2,735,364 |
Connealy received $2.3M in option awards, accounting for 83% of the total pay in 2021.
Connealy also received $252.5K in non-equity incentive plan, $195.5K in salary and $18.8K in other compensation.
Rankings
In 2021, Pamela Connealy's compensation ranked 4,799th out of 12,415 executives tracked by ExecPay. In other words, Connealy earned more than 61.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,799 out of 12,415 | 61st |
Division Manufacturing | 2,006 out of 5,505 | 64th |
Major group Chemicals And Allied Products | 849 out of 2,375 | 64th |
Industry group Drugs | 759 out of 2,096 | 64th |
Industry Pharmaceutical Preparations | 542 out of 1,546 | 65th |
Source: SEC filing on April 28, 2022.
Connealy's colleagues
We found two more compensation records of executives who worked with Pamela Connealy at Pyxis Oncology in 2021.